Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BIA 2-093 Formulations in Healthy Volunteers
NCT02279667Phase 1Completed
- Sponsor
- BIAL
- Start
- Feb 2004
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine acetate in epilepsy (3 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration, Time of Occurrence of Cmax and 2 more. Started Feb 2004; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02279667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279667.